Last reviewed · How we verify

SPM 907 — Competitive Intelligence Brief

SPM 907 (SPM 907) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: S1P1 receptor antagonist. Area: Immunology.

phase 3 S1P1 receptor antagonist S1P1 (Sphingosine-1-phosphate receptor 1) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

SPM 907 (SPM 907) — Pfizer. SPM 907 is a selective antagonist of the S1P1 receptor that reduces lymphocyte egress from lymphoid tissues, thereby decreasing circulating lymphocyte counts.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
SPM 907 TARGET SPM 907 Pfizer phase 3 S1P1 receptor antagonist S1P1 (Sphingosine-1-phosphate receptor 1)
JYB1904 JYB1904 Jemincare phase 3 S1P1 receptor antagonist S1P1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (S1P1 receptor antagonist class)

  1. AbbVie · 1 drug in this class
  2. Altheos, Inc. · 1 drug in this class
  3. Jemincare · 1 drug in this class
  4. Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SPM 907 — Competitive Intelligence Brief. https://druglandscape.com/ci/spm-907. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: